The Cardiovascular Safety Profile of Renzapride, a Novel Treatment for Irritable Bowel Syndrome

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.35, Iss.6, 2007-11, pp. : 848-866

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome

By Scarpellini Emidio Tack Jan

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 11, 2008-11 ,pp. : 1663-1670

Informa Healthcare

Access to resources Recommend Favorite

Novel therapies in the treatment of irritable bowel syndrome

By Berrada Driss Lembo Tony

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 4, 2003-04 ,pp. : 635-645

Informa Healthcare

Access to resources Recommend Favorite

Safety Profile of Tegaserod, a 5-HT 4 Receptor Agonist, for the Treatment of Irritable Bowel Syndrome

By Hasler W.L. Schoenfeld P.

Drug Safety, Vol. 27, Iss. 9, 2004-01 ,pp. : 619-631

Adis International

Access to resources Recommend Favorite

The safety of novel drugs used to treat irritable bowel syndrome

By Mozaffari Shilan Nikfar Shekoufeh Abdollahi Mohammad

Expert Opinion on Drug Safety, Vol. 13, Iss. 5, 2014-05 ,pp. : 625-638

Informa Healthcare

Access to resources Recommend Favorite

The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome

By McLaughlin John Houghton Lesley A

Expert Opinion on Drug Safety, Vol. 5, Iss. 2, 2006-03 ,pp. : 313-327

Informa Healthcare

Access to resources Recommend Favorite